Skip to main content
Clinical Trials/NCT06467734
NCT06467734
Not yet recruiting
Not Applicable

Prospective Cohort Study of Synovial Biomarkers in the Diagnosis and Prediction of Periprosthetic Joint Infection

First Affiliated Hospital of Xinjiang Medical University0 sites200 target enrollmentAugust 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prospective Cohort Study of Synovial Biomarkers in the Diagnosis and Prediction of Periprosthetic Joint Infection
Sponsor
First Affiliated Hospital of Xinjiang Medical University
Enrollment
200
Primary Endpoint
Joint fluid target protein detection
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Prosthetic Joint Infection (PJI) is one of the severe complications following arthroplasty. With the global aging population, the number of patients undergoing primary joint replacement surgeries is increasing, leading to a rise in PJI cases. Although the incidence of PJI is generally low, the impact on patients can be catastrophic. Once an infection occurs, it is further complicated by the rising global antibiotic resistance, imposing a significant economic burden on patients. Therefore, improving the diagnostic rate of PJI is crucial. Currently, various infection markers are used in the diagnosis of PJI. However, there is still a lack of highly sensitive and specific markers to effectively diagnose PJI, necessitating the exploration of new infection markers. This study aims to investigate novel infection markers for the diagnosis of PJI, providing evidence for its diagnosis and subsequent treatment. In this research, we will prospectively collect data from patients undergoing primary joint replacement and those developing PJI from June 2024 to December 2026. These patients will be categorized into non-infection and infection groups. By collecting and analyzing general patient data, surgery-related information, and infection-related indicators from preoperative joint fluid and blood samples, we aim to further evaluate the predictive value of these infection markers for PJI.

Registry
clinicaltrials.gov
Start Date
August 1, 2024
End Date
December 31, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
First Affiliated Hospital of Xinjiang Medical University
Responsible Party
Principal Investigator
Principal Investigator

Long Hua

Doctor

First Affiliated Hospital of Xinjiang Medical University

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years old, gender is not limited;
  • The experimental group met the diagnostic criteria of chronic periprosthesis infection after joint replacement according to the 2018 Musculoskeletal Infection Association; The control group was eligible for primary replacement patients who excluded periprosthesis infection.
  • Voluntary and signed informed consent.

Exclusion Criteria

  • Patients with immune-related arthritis such as rheumatoid and rheumatism were excluded;
  • Radiotherapy and chemotherapy are required due to neoplastic diseases;
  • Receiving systemic glucocorticoid therapy (prednisone \> 10mg/ day or equivalent hormone medication);
  • Severe immunodeficiency diseases (such as stage 3 HIV, sickle cell anemia, splenectomy, etc.);
  • Have a history of drug abuse;
  • Use immunosuppressive drugs to treat bone marrow or other transplants;
  • Pregnant, parturient and lactating women;
  • Participating in other clinical trials;
  • Researchers consider other reasons not appropriate for clinical trial participants.

Outcomes

Primary Outcomes

Joint fluid target protein detection

Time Frame: One day before surgery or one day after surgery

To detect new target proteins by elisa test.

Secondary Outcomes

  • Erythrocyte sedimentation rate (ESR)(One day before sugery and two year after surgery)
  • Doppler lower extremity vascular color ultrasound(One day before surgery and three day after surgery)
  • Alanine Aminotransferase (ALT)(One day before surgery and one day after surgery)
  • X-ray(One day before surgery and two years after surgery)
  • C-reactive protein (CRP)(One day before sugery and two year after surgery)
  • Synovial fluid white blood cell count (SF-WBC)(One day before surgery and one day after surgery)
  • Synovial fluid polymorphonuclear cells (SF-PMN)(One day before surgery and one day after surgery)
  • American Knee Society Score (AKS score)(One day before surgery, two years after surgery)
  • The Hip Harris Score (HHS)(One day before surgery, two years after surgery)
  • Serum Creatinine(One day before surgery and one day after surgery)
  • Blood Urea Nitrogen (BUN)(One day before surgery and one day after surgery)
  • Aspartate Aminotransferase (AST)(One day before surgery and one day after surgery)

Similar Trials